Esya utilizes patented DNA nanoprobes and AI-driven multi-omics analytics to diagnose neurodegenerative diseases like Alzheimer's and Parkinson's before symptoms appear. Their technology provides precise insights into cellular functions, enabling early detection and personalized treatment plans for improved patient outcomes.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for neurodegenerative diseases like Alzheimer's and Parkinson's often rely on the appearance of clinical symptoms, which limits the potential for early intervention and personalized treatment strategies. Traditional biomarker assays may lack the sensitivity to detect subtle changes in cellular function that precede overt disease manifestations.
Solution
Esya utilizes patented DNA nanotechnology-based probes and AI-driven multi-omics analytics to enable early diagnosis and personalized treatment plans for neurodegenerative diseases. Their approach combines intracellular multi-omics analysis, including proteomics, with advanced AI models to uncover novel pathways associated with brain health. Esya's assays quantify key chemicals within cellular compartments, such as endosomes and lysosomes, providing insights into disease mechanisms. The platform supports biomarker discovery, patient stratification, and assessment of drug efficacy in clinical trials.
Target Audience
Esya's primary customers include biopharma companies, biotech firms, and clinical researchers focused on neurodegenerative diseases, as well as clinicians seeking early diagnostic tools and personalized treatment strategies.
Features
- Patented DNA nanoprobes designed to capture sub-cellular properties with high precision
- NULISA (NUcleic acid Linked Immuno-Sandwich Assay) platform for targeted proteomics with attomolar sensitivity and high multiplexing
- AI-driven multi-omics data analysis platform for robust insights into disease pathways
- Voltair: DNA-based sensor for absolute membrane potential of cell and organelle membranes
- CalipHluor: DNA-based, ratiometric combination reporter of pH and Ca2+ levels
- Clensor: pH-independent, ratiometric Cl- sensor for detecting chloride ion concentrations
- GLP & CLIA compliance to ensure biomarker assays meet the highest quality standards